证券代码：603669 证券简称：灵康药业 公告编号：2023-048 灵康药业集团股份有限公司 关于控股股东股票质押式回购交易延期购回及 补充质押的公告 2023 年 9 月 15 日，灵康药业集团股份有限公司（以下简称"灵康药业"或 "本公司"）接到公司控股股东灵康控股关于股票质押式回购交易延期购回及补 充质押的通知，现将相关情况公告如下： 一、本次股票质押式回购交易延期购回及补充质押的具体情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至公告披露日,公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接持有公司股份 33,965.28 万股无限售流通股股票，占公司总股本 的 47.09%，灵康控股累计质押公司股票数量为 15,265.96 万股，占其持有公司 股份总数的 44.95%，占公司总股本的 21.17%。 灵康控股本次办理延期购回及补充质押的业务，不涉及新增融资安排。 截至目前，灵康控股所持股份的质押风险可控，不存在引发平仓或被强制平仓的 风险。 2023 年 9 月 13 ...

证券代码：603669 证券简称：灵康药业 公告编号：2023-047 关于公司监事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）监事会于 2023 年 8 月 25 日收到监事杨栋先生的书面辞职报告，因工作安排，杨栋先生申请辞去担任的监 事及监事会主席职务，其辞职后仍继续在公司担任其他职务。 灵康药业集团股份有限公司董事会 2023 年 8 月 26 日 灵康药业集团股份有限公司 根据《公司法》、《公司章程》等有关规定，杨栋先生的辞职将导致公司监事 会成员低于法定最低人数，其辞职申请将在公司股东大会选举产生新任监事后生 效。在此期间，杨栋先生仍将按照有关法律、行政法规和公司《章程》的规定继 续履行监事职责。公司将按照法定程序尽快完成监事补选工作。 杨栋先生在担任公司监事及监事会主席期间恪尽职守、勤勉尽责，公司及公 司董事会对杨栋先生任职期间为公司发展做出的重要贡献表示衷心感谢。 特此公告。 1 ...

证券代码：603669 证券简称：灵康药业 公告编号：2023-046 灵康药业集团股份有限公司 2023 年半年度关于募集资金年度存放与使用情况的专项报告 1. 2015 年首次公开发行股票 经中国证券监督管理委员会证监许可〔2015〕828 号文核准，并经上海证券交易所同意， 本公司由主承销商中信证券股份有限公司采用向社会公开方式，向社会公众公开发行人民 币普通股（A 股）股票 6,500 万股，发行价为每股人民币 11.70 元，共计募集资金 76,050.00 万元，扣除发行费用人民币 5,755.03 万元后，实际募集资金净额 70,294.97 万元。上述募 集资金到位情况业经天健会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》（天 健验〔2015〕150 号）。 2. 2020 年公开发行可转换公司债券 经中国证券监督管理委员会证监许可〔2020〕2640 号文核准，并经上海证券交易所同 意，本公司由本次发行保荐人及联席主承销商中信证券股份有限公司采用包销方式，向社会 公众公开发行可转换公司债券 525 万张，每张面值为人民币 100 元，按面值发行，发行总额 为人民币 52,500.0 ...

一、董事会会议召开情况 灵康药业集团股份有限公司（以下简称"公司"）第四届董事会第九次会议 通知于 2023 年 8 月 14 日以电话、电子邮件、传真等形式发出，会议于 2023 年 8 月 24 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由董事 长陶灵萍召集并主持，应出席本次会议的董事 7 人，实际出席本次会议的董事 7 人。公司监事、高级管理人员列席了会议。本次会议的召集、召开和表决程序符 合有关法律、法规和《公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 1、审议通过了《2023 年半年度报告及摘要》 具体内容详见上海证券交易所网站（www.sse.com.cn）发布的《2023 年半年 度报告及摘要》。 表决结果：同意票 7 票，反对票 0 票，弃权 0 票。 证券代码：603669 证券简称：灵康药业 公告编号：2023-044 灵康药业集团股份有限公司 第四届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 具体内容详见上海证券交易所网站（www. ...

证券代码：603669 证券简称：灵康药业 公告编号：2023-045 灵康药业集团股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 监事会会议召开情况 （2）公司 2023 年半年度报告及摘要公允地反映了公司报告期内的财务状况 和经营成果，所包含的信息能从各个方面真实地反映出公司报告期内的经营管理 和财务状况等事项； （3）监事会在提出本意见前，未发现所载资料存在虚假记载、误导性陈述 或者重大遗漏的情形； （4）监事会在提出本意见前，未发现参与编制和审议的人员有违反保密规 定的行为。 具体内容上海证券交易所网站（www.sse.com.cn）披露的公告。 灵康药业集团股份有限公司（以下简称"公司"）第四届监事会第九次会议 通知于 2023 年 8 月 14 日以电话、电子邮件、传真等形式发出，会议于 2023 年 8 月 24 日在浙江灵康药业有限公司会议室以现场结合通讯方式召开。会议由监 事会主席杨栋先生召集并主持,会议应出席 3 人,实际出席 3 人。本次会议参与表 ...

灵康药业集团股份有限公司 关于子公司盐酸艾司洛尔注射液 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南灵康制药有限公司（以下简称"灵康制药"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于"盐酸艾司洛尔注射液"（以下简 称"该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致 性评价。现将有关情况公告如下： 一、药品基本情况 药物名称：盐酸艾司洛尔注射液 剂型：注射剂 注册分类：化学药品 规格：10ml:0.1g 受理号：CYHB2250357 证券代码：603669 证券简称：灵康药业 公告编号：2023-043 上市许可持有人：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 生产企业：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 药品批准文号：国药准字 H20237092 审批结论：根据《 ...

证券代码：603669 证券简称：灵康药业 公告编号：2023-033 投资者可于 2023 年 6 月 19 日 17:30 前将相关问题，通过传真、电话、邮件 等形式将需要了解的情况和关心的问题提供给公司，公司将会在本次说明会上对 投资者普遍关注的问题进行回答。 灵康药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日、4 月 29 日在上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体披露了 《2022 年年度报告》、《2023 年第一季度报告》。为便于广大投资者更加全面深入 了解公司经营情况，公司将通过网络平台在线交流的方式召开 2022 年度暨 2023 年第一季度业绩说明会（以下简称"说明会"）。届时将针对公司发展的经营业绩、 利润分配、发展规划等投资者关心的问题与广大投资者进行交流和沟通，同时广 泛听取投资者的意见和建议。 一、说明会类型 本次业绩说明会以网络方式召开，公司将针对 2022 年年度及 2023 年第一季 度业绩和经营情况与投资者进行交流，并对投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 灵康药业集团股份有限公司 关于召开 2 ...

灵康药业集团股份有限公司 证券简称：灵康药业 证券代码：603669 编号：2022-001 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|-----------------------------| | | 特定对象调研 | □分析师会议 | □媒体采访 | | 投资者关系活动类型 | 业绩说明会 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 ...

Financial Performance - The company's operating revenue for Q3 2021 was CNY 176,044,813.85, a decrease of 40.57% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was CNY 10,102,189.45, down 86.72% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,753,668.90, a decline of 77.60% compared to the previous year[5]. - The basic earnings per share for Q3 2021 was CNY 0.01, a decrease of 90.91% from the same period last year[6]. - The weighted average return on equity for Q3 2021 was 0.69%, a decrease of 4.97 percentage points year-on-year[6]. - The net profit for the year-to-date was CNY 78,884,394.04, down 48.22% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2021 was CNY 653,972,322.58, a decrease of 15.1% compared to CNY 769,993,995.94 in the same period of 2020[19]. - Net profit for the first three quarters of 2021 was CNY 78,884,394.04, a decline of 48.2% from CNY 152,359,597.78 in the same period of 2020[20]. - The company reported a total profit of CNY 91,256,457.38 for the first three quarters of 2021, down 46.5% from CNY 169,941,654.48 in the previous year[20]. - Other income for the first three quarters of 2021 was CNY 24,252,019.56, a significant decrease from CNY 87,793,401.54 in the previous year[19]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,695,794,485.52, a decrease of 0.75% from the end of the previous year[6]. - As of September 30, 2021, total assets amounted to RMB 2,695,794,485.52, a slight decrease from RMB 2,716,208,544.25 at the end of 2020[15]. - Current assets totaled RMB 2,015,644,139.68, compared to RMB 2,038,816,387.03 at the end of 2020, indicating a decrease of approximately 1.4%[16]. - Total liabilities decreased slightly to RMB 1,224,423,387.15 from RMB 1,236,333,673.38, a reduction of about 1%[17]. - The company's equity attributable to shareholders was RMB 1,471,371,098.37, down from RMB 1,479,874,870.87, indicating a decrease of approximately 0.6%[17]. - The total liabilities included short-term borrowings of 389,746,221.99 RMB, unchanged from the previous period[27]. - The company's total equity stood at approximately $1.48 billion, with paid-in capital of $713.44 million and retained earnings of $327.62 million[28]. - The total liabilities and equity amounted to CNY 2,695,794,485.52 as of the end of the reporting period[18]. - The total liabilities and equity combined were approximately $2.718 billion, indicating a balanced financial structure[28]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY -6,423,057.02, reflecting a significant decline[6]. - The net cash flow from operating activities was -6,423,057.02 RMB, a decrease from 21,215,904.94 RMB in the previous quarter[24]. - Total cash inflow from investment activities was 1,111,232,123.41 RMB, compared to 656,386,626.08 RMB in the previous quarter[24]. - The net cash flow from investment activities was -603,007,209.64 RMB, a decline from 209,087,254.20 RMB in the previous quarter[24]. - Cash inflow from financing activities totaled 482,793,377.72 RMB, up from 383,664,091.64 RMB in the previous quarter[25]. - The net cash flow from financing activities was 19,628,221.60 RMB, compared to 207,661,556.85 RMB in the previous quarter[25]. - The ending cash and cash equivalents balance was 964,807,350.04 RMB, slightly up from 925,992,921.30 RMB in the previous quarter[25]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,368[12]. - The number of shares held by the largest shareholder, Lingkang Holdings Group Co., Ltd., is 339,652,800, representing 47.10% of total shares[13]. Operational Challenges - The company attributed the revenue decline primarily to centralized procurement and nationwide price linkage impacts[10]. - The company reported a significant cash outflow in operating activities, indicating potential liquidity challenges[24]. - The company has not disclosed any new product developments or market expansion strategies in the current report[14]. Research and Development - Research and development expenses for the first three quarters of 2021 were CNY 18,658,295.54, an increase of 44.3% compared to CNY 12,969,101.39 in the same period of 2020[19]. Accounting Standards - The company implemented a new leasing standard effective January 1, 2021, which did not significantly impact financial results or cash flows[29]. - There were no significant adjustments or retrospective changes affecting the financial statements[29].

Financial Performance - Basic earnings per share for the first half of 2021 was CNY 0.10, a decrease of 9.09% compared to CNY 0.11 in the same period last year[19]. - The diluted earnings per share also stood at CNY 0.10, reflecting the same 9.09% decline compared to the previous year[19]. - The net profit attributable to shareholders decreased by 9.84% to RMB 68.78 million from RMB 76.29 million year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 6.61% to RMB 38.65 million from RMB 36.25 million year-on-year[21]. - The company's operating revenue for the first half of the year was RMB 477.93 million, an increase of 0.88% compared to RMB 473.77 million in the same period last year[21]. - The total equity attributable to shareholders decreased to CNY 1,405,990,293.02 from CNY 1,479,874,870.87, indicating a decline in shareholder value[117]. - The company reported a comprehensive income of CNY 68,782,204.59 for the period, indicating some recovery despite overall losses[139]. Cash Flow and Investments - The net cash flow from operating activities improved significantly to RMB 43.96 million, a turnaround from a negative RMB 36.60 million in the previous year[21]. - The net cash flow from operating activities improved due to optimized sales networks and reduced circulation costs[37]. - The company received government subsidies amounting to CNY 21.63 million during the first half of 2021, contributing positively to its financial performance[38]. - The company's cash and cash equivalents decreased by 36.22% to CNY 999.37 million, primarily due to investments in financial products[39]. - The total amount of trading financial assets surged by 325.68% to CNY 766.22 million, indicating a significant increase in investment activities[39]. - Cash inflow from investment activities was approximately ¥564.25 million, while cash outflow was ¥1.16 billion, resulting in a net cash outflow of ¥592.24 million from investment activities[131]. Research and Development - The company has increased its R&D investment, with ongoing projects covering major disease areas such as oncology, liver disease, and cardiovascular diseases[28]. - The R&D team consists of over 180 members, with a focus on market-driven development and increased R&D investment, leading to a growth trend in R&D expenses[30]. - Research and development expenses for the first half of 2021 were CNY 12,304,214.76, up from CNY 11,403,839.41, reflecting an increase of approximately 7.87%[123]. Market and Product Development - The company is actively expanding into high-margin new products, particularly in the cardiovascular field, with significant progress made[25]. - The company aims to expand its product pipeline by leveraging existing sales channels and exploring new varieties through licensing and acquisitions[29]. - The company is actively developing high-margin new products in cardiovascular, liver disease, and hypertension treatment areas[29]. Environmental Compliance - The company maintained compliance with environmental standards, with no exceedances reported for wastewater and air emissions[61][63]. - The company reported a total nitrogen discharge of 0.223 tons, which is below the standard limit of 30 mg/L[62]. - The company’s wastewater discharge included a BOD5 level of 0.189 tons, well below the standard limit of 20 mg/L[62]. Corporate Governance and Compliance - The company has not faced any significant risks that would affect the authenticity and completeness of the semi-annual report[6]. - The company has established measures to protect minority investors' interests during the issuance of convertible bonds, including commitments to not interfere with management activities[78]. - The company has not engaged in any violations regarding guarantees during the reporting period[80]. Shareholder Information - The largest shareholder, Lingkang Holdings Group Co., Ltd., holds 339,652,800 shares, representing 47.61% of total shares, with 174,165,800 shares pledged[98]. - The total number of ordinary shareholders was 16,187[96]. - The company issued 5.25 million convertible bonds with a total amount of 525 million RMB, with a maturity of 6 years[94]. Financial Position - Total assets at the end of the reporting period were RMB 2.77 billion, an increase of 1.99% from RMB 2.72 billion at the end of the previous year[21]. - Total liabilities increased to ¥1,364,348,004.43, up from ¥1,236,333,673.38, resulting in a debt-to-asset ratio of 49.25% compared to 45.52% previously[111]. - The company's credit rating remains stable at AA- as per the report from Dongfang Jincheng International Credit Rating Co., Ltd.[111]. Risk Factors - The company faces risks related to market competition, regulatory changes, new product development, and quality control[52]. - The company has established a mature R&D system but still faces inherent risks in new product development[53].